Puma Biotechnology, Inc. (PBYI): Total Assets
$216.30M
As of 2025-12-31
$192.74M
As of 2026-06-30
-0.9%
3-year compound annual growth
-2.4%
5-year compound annual growth
-1.0%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $216.30M | +1.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $213.33M | -7.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $230.53M | +3.8% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $222.06M | -2.0% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $226.59M | -7.2% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $244.22M | +4.0% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $234.91M | -9.3% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $259.12M | +56.5% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $165.53M | -34.5% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $252.79M | +5.4% | 2018-03-09, Balance as of period end |
| 2015-12-31 | $239.84M | +47.4% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $162.76M | +55.9% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $104.37M | -31.2% | 2015-03-02, Balance as of period end |
| 2012-12-31 | $151.70M | +173.8% | 2014-03-03, Balance as of period end |
| 2011-12-31 | $55.40M | n/a | 2013-04-01, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $216.30M | +1.4% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $364.39M | -24.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $376.56M | +70.6% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $1.11B | -1.3% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $338.02M | -45.1% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $670.77M | -2.1% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $1.14B | -1.0% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $726.16M | -11.8% |
Compare PBYI, ANAB, AKBA, IDYA side by side · Screen every company in Pharmaceutical Preparations ↗